DeepMed Research

ShengJing Hospital of China Medical University (China Medical University No.2 Ho spital )

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website: http://www.sj-hospital.org

Clinical Trials

Magnetic Resonance Elastography in Glioma: Exploring Tumor Stiffness and Adhesion

Not Applicable

Recruiting

Conditions: Glioma

Interventions: Diagnostic Test: Magnetic Resonance Elastography
Procedure: Assessment and Recording

First Posted Date: 2023-08-14

Last Posted Date: 2024-12-04

Lead Sponsor: Shengjing Hospital

Target Recruit Count: 100

Registration Number: NCT05990244

Locations: 🇨🇳
Shengjing Hospital, Shenyang, Liaoning, China

VTE Risk Prevention System Based on Big Data Analysis and Multimodule System

Recruiting

Conditions: Recruiting

First Posted Date: 2023-08-01

Last Posted Date: 2023-08-01

Lead Sponsor: Shengjing Hospital

Target Recruit Count: 100000

Registration Number: NCT05969951

Locations: 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China

MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion Assessment

Not Applicable

Recruiting

Conditions: Spinal Cord Tumors

Interventions: Diagnostic Test: Magnetic Resonance Elastography
Procedure: Assessment and Recording

First Posted Date: 2023-07-24

Last Posted Date: 2023-07-27

Lead Sponsor: Shengjing Hospital

Target Recruit Count: 20

Registration Number: NCT05957679

Locations: 🇨🇳
Shengjing Hospital, Shenyang, Liaoning, China

rhBNP in Type 3 Pulmonary Hypertension

Phase 4

Conditions: Group 3 Pulmonary Hypertension

Interventions: Drug: recombinant human brain natriuretic peptide
Drug: Placebo

First Posted Date: 2023-02-08

Last Posted Date: 2023-10-10

Lead Sponsor: Shengjing Hospital

Target Recruit Count: 72

Registration Number: NCT05716984

Locations: 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳
Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Pyrotinib
Drug: Trastuzumab
Drug: Pertuzumab
Drug: Dalpiciclib
Drug: Docetaxel
Drug: Carboplatin
Drug: Letrozole
Drug: Gonadotropin-releasing hormone agonist

First Posted Date: 2022-12-06

Last Posted Date: 2023-03-20

Lead Sponsor: Shengjing Hospital

Target Recruit Count: 236

Registration Number: NCT05638594

Locations: 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China

A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Phase 2

Recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Drug: SHR-A1811
Drug: Pyrotinib

First Posted Date: 2022-12-02

Last Posted Date: 2024-07-05

Lead Sponsor: Shengjing Hospital

Target Recruit Count: 65

Registration Number: NCT05635487

Locations: 🇨🇳
Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, China

Management of FI After Surgery of ARM

Completed

Conditions: Childhood ALL
Fecal Incontinence
Anorectal Malformations

First Posted Date: 2022-11-18

Last Posted Date: 2023-04-12

Lead Sponsor: Shengjing Hospital

Target Recruit Count: 108

Registration Number: NCT05621629

Locations: 🇨🇳
Shengjing Hospital, Shenyang, Liaoning, China

Frozen Embryo Transfer Pregnancy Outcomes Prediction by Microbiome and Transcriptome

Recruiting

Conditions: Microbiome
Infertility

Interventions: Other: no intervention

First Posted Date: 2022-09-19

Last Posted Date: 2022-09-19

Lead Sponsor: Shengjing Hospital

Target Recruit Count: 300

Registration Number: NCT05545631

Locations: 🇨🇳
Xiuxia Wang, Shenyang, Liaoning, China

A 14-item Questionnaire Regarding Career Preferences Among Chinese Medical Undergraduate Students.

Active, not recruiting

Conditions: Career Burnout
Student Burnout

Interventions: Other: Questionnaire Survey

First Posted Date: 2022-09-08

Last Posted Date: 2023-11-02

Lead Sponsor: Shengjing Hospital

Target Recruit Count: 500

Registration Number: NCT05531487

Locations: 🇨🇳
Shenjing Hospital of CHINA MEDICAL UNIVERSITY, Shenyang, Liaoning, China

A Single Arm Study of Traditional Chinese Medicine for Plasma Cell Mastitis

Phase 2

Recruiting

Conditions: Plasma Cell Mastitis

Interventions: Drug: Traditional Chinese medicine

First Posted Date: 2022-09-07

Last Posted Date: 2022-09-07

Lead Sponsor: Shengjing Hospital

Target Recruit Count: 50

Registration Number: NCT05530226

Locations: 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy